NMPA Releases 59th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 59th batch of reference drugs for...
Drug
Harbour BioMed Doses First Subject in Phase I Study for HBM9378 in China
China-based Harbour BioMed (HKG: 2142) has announced the completion of the first subject dosing in...
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...
Fosun Pharma Launches 20ml SPSB Liquid Product in US Market
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...
Tris Pharma and Pediatrix Therapeutics’ ADHD Drug Gains Priority Review in China
The Center for Drug Evaluation (CDE) has indicated that the methylphenidate hydrochloride oral sustained-release dry...
Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study
China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
Brii Biosciences Publishes Positive Phase I Results for PPD Therapy BRII-296
China-based Brii Biosciences Limited (HKG: 2137) has published the top-line results from a Phase I...
Sino Biopharmaceutical’s TDI01 Receives Clinical Trial Approval for COVID-19
China’s Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Beijing Tide Pharmaceutical Co....
Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema
China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal...
Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval...
Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...
HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya
Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback...
Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review
China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276)...
Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China
China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has...
AstraZeneca and Merck’s Lynparza Receives New Approval in China
UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced...
Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...
Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...